Aceon Medication Summary
No separate FDA Medication Guide was found for this label. This summary is based on FDA/DailyMed prescribing information.
What is this medication?
This medication is described in FDA/DailyMed prescribing information. No separate FDA Medication Guide was found for this label. This summary is based on FDA/DailyMed prescribing information.
What is this medication used for?
ACEON is indicated for the treatment of patients with essential hypertension (1.1)ACEON is indicated for treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction (1.2)
What should I know before taking it?
ACEON® (perindopril erbumine) is contraindicated in patients known to be hypersensitive (including angioedema) to this product or to any other ACE inhibitor. ACEON is also contraindicated in patients with hereditary or idiopathic angioedema. Do not co-administer aliskiren with ACEON in patients with diabetes [see Drug Interactions (7.8)].
What important warnings are listed?
When pregnancy is detected, discontinue ACEON as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning.
How is this medication usually taken?
Tablets are oblong with a score on one side. 2 mg tablet is white and debossed on the unscored side with "ACN 2". 4 mg tablet is pink and debossed on the unscored side with "ACN 4". 8 mg tablet is salmon and debossed on the unscored side with "ACN 8".
What side effects are listed?
Because clinical trials are conducted under widely varying conditions, adverse event rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
What interactions are listed?
Diuretics: Excessive drop in blood pressure (7.1)Potassium-sparing diuretics/potassium supplements: Hyperkalemia (7.2)Lithium: Increase serum lithium levels, symptoms of lithium toxicity (7.3)Injectable gold: Nitritoid reactions (facial flushing, nausea, vomiting, and hypotension) (7.4)NSAID use may lead to increased risk of renal impairment and loss of antihypertensive effect (7.7)Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia (7.8).
Where can I find the official prescribing information?
Review the full prescribing information on DailyMed: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97a9e8bf-91ed-4256-97d4-f9504bb01373
⚠️ Disclaimer
This summary is for educational purposes only and is not medical advice. Always consult your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine. Read full medical disclaimer.